Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24334191,total chromatographic run time,The total chromatographic run time was 2.0 min and calibration curves were linear over the concentration range of 0.10-20.00 ng/mL for Olanzapine and 0.50-50.00 ng/mL for Fluoxetine.,Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24334191/),min,2.0,3333,DB00334,Olanzapine
≥,24334191,recoveries,The recoveries obtained for the Olanzapine and its IS was ≥87% and Fluoxetine and its IS was ≥91%.,Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24334191/),%,87,3334,DB00334,Olanzapine
≥,24334191,recoveries,The recoveries obtained for the Olanzapine and its IS was ≥87% and Fluoxetine and its IS was ≥91%.,Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24334191/),%,91,3335,DB00334,Olanzapine
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB00334,Olanzapine
,18796323,C(max),"The mean C(max) and the mean area under the plasma concentration-time curve from time zero to 120 h (AUC0-->120) of the heavy-smoking patients was 9.3+/-4.3 ng/ml (65.2% reduction compared to the non-smokers) and 302.4+/-167.8 h ng/ml (67.6% reduction compared to the non-smokers), respectively.",Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796323/),[ng] / [ml],9.3,5842,DB00334,Olanzapine
,18796323,area under the plasma concentration-time curve from time zero to 120 h (AUC0-->120),"The mean C(max) and the mean area under the plasma concentration-time curve from time zero to 120 h (AUC0-->120) of the heavy-smoking patients was 9.3+/-4.3 ng/ml (65.2% reduction compared to the non-smokers) and 302.4+/-167.8 h ng/ml (67.6% reduction compared to the non-smokers), respectively.",Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796323/),[h·ng] / [ml],302.4,5843,DB00334,Olanzapine
,24473487,AUC,"The mean AUC was 747.6 ng h/mL (95% CI = 524.5, 970.7) for the benefit group (n = 16) and 754.1 (95% CI = 505.9, 1002.4) for the risk group (n = 15).",Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24473487/),[h·ng] / [ml],747.6,8354,DB00334,Olanzapine
,24473487,AUC,"The mean AUC was 747.6 ng h/mL (95% CI = 524.5, 970.7) for the benefit group (n = 16) and 754.1 (95% CI = 505.9, 1002.4) for the risk group (n = 15).",Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24473487/),[h·ng] / [ml],754.1,8355,DB00334,Olanzapine
,24473487,AUC,The benefit-risk AUC breakpoint was 524.5 ng h/mL and the corresponding oral olanzapine dose that optimizes benefit-risk balance was 17.8 mg/d.,Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24473487/),[h·ng] / [ml],524.5,8356,DB00334,Olanzapine
,26960680,di,"The model optimized fast dissolving film prepared from the dispersion was physically and chemically stable, demonstrated short disintegration time (8.5 s), fast dissolution (97% in 10 min) and optimum tensile strength (4.9 N/cm2).",In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),s,8.5,9529,DB00334,Olanzapine
,26960680,tensile strength,"The model optimized fast dissolving film prepared from the dispersion was physically and chemically stable, demonstrated short disintegration time (8.5 s), fast dissolution (97% in 10 min) and optimum tensile strength (4.9 N/cm2).",In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),[n] / [cm2],4.9,9530,DB00334,Olanzapine
,26960680,bioavailability,The results of in vivo data indicated high bioavailability (144 ng h/mL) and maximum plasma concentration (14.2 ng/mL) compared with the marketed references.,In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),[h·ng] / [ml],144,9531,DB00334,Olanzapine
,26960680,maximum plasma concentration,The results of in vivo data indicated high bioavailability (144 ng h/mL) and maximum plasma concentration (14.2 ng/mL) compared with the marketed references.,In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),[ng] / [ml],14.2,9532,DB00334,Olanzapine
,29402457,zeta potential,It was found that the batch with stearyl amine has a zeta potential of 28.39 mV which confers stability to the dispersion.,Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29402457/),mv,28.39,9961,DB00334,Olanzapine
,20824513,Relative bioavailability,Relative bioavailability of the test tablet was calculated as 94%.,Controlled release matrix tablets of olanzapine: influence of polymers on the in vitro release and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20824513/),%,94,16810,DB00334,Olanzapine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,87,23947,DB00334,Olanzapine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,30,23948,DB00334,Olanzapine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,57,23949,DB00334,Olanzapine
,9010634,peak plasma concentration,"Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),[ng] / [ml],11,23950,DB00334,Olanzapine
,9010634,peak plasma concentration,"Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),[eq·ng] / [ml],39,23951,DB00334,Olanzapine
,9010634,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),h,27,23952,DB00334,Olanzapine
,9010634,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),h,59,23953,DB00334,Olanzapine
,17536749,half-life,"In this study's series of serum concentrations, a two-phase elimination was seen, with an initial elimination half-life of about 24 h during the first 3 days, followed by a second phase with a half-life of about 2.5 days.",Serum levels of olanzapine in a non-fatal overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17536749/),d,2.5,25332,DB00334,Olanzapine
,10870093,terminal half-life,The terminal half-life of olanzapine in plasma was 2.5 h and in tissues it ranged from 3 to 5.2 h.,Pharmacokinetics and tissue distribution of olanzapine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870093/),h,2.5,28115,DB00334,Olanzapine
,10870093,terminal half-life,The terminal half-life of olanzapine in plasma was 2.5 h and in tissues it ranged from 3 to 5.2 h.,Pharmacokinetics and tissue distribution of olanzapine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870093/),h,3 to 5.2,28116,DB00334,Olanzapine
,29982313,recoveries,"The absolute mean recoveries were found to be in the replicate range of 87.12-94.47%, respectively.",Supported liquid extraction and LC-MS-MS determination of iloperidone and olanzapine in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29982313/),%,87.12-94.47,53002,DB00334,Olanzapine
,27060853,Half-life,Half-life and sex effect on sertraline apparent clearance (males averaging 50% higher (p < 0.005); 96.6 l/h vs 64.8 in female subjects) were similar to previous reports.,"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060853/),[l] / [h],96.6,54033,DB00334,Olanzapine
,27060853,apparent clearance,Half-life and sex effect on sertraline apparent clearance (males averaging 50% higher (p < 0.005); 96.6 l/h vs 64.8 in female subjects) were similar to previous reports.,"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060853/),[l] / [h],96.6,54034,DB00334,Olanzapine
,27060853,apparent clearance,Half-life and sex effect on sertraline apparent clearance (males averaging 50% higher (p < 0.005); 96.6 l/h vs 64.8 in female subjects) were similar to previous reports.,"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060853/),,64.8,54035,DB00334,Olanzapine
,27837829,recoveries,"MEPS recoveries were between 92% and 98%, with intra- and interday variabilities below 15%.","A sensitive capillary LC-UV method for the simultaneous analysis of olanzapine, chlorpromazine and their FMO-mediated N-oxidation products in brain microdialysates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27837829/),%,92,58594,DB00334,Olanzapine
,27837829,recoveries,"MEPS recoveries were between 92% and 98%, with intra- and interday variabilities below 15%.","A sensitive capillary LC-UV method for the simultaneous analysis of olanzapine, chlorpromazine and their FMO-mediated N-oxidation products in brain microdialysates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27837829/),%,98,58595,DB00334,Olanzapine
,27837829,recoveries,"MEPS recoveries were between 92% and 98%, with intra- and interday variabilities below 15%.","A sensitive capillary LC-UV method for the simultaneous analysis of olanzapine, chlorpromazine and their FMO-mediated N-oxidation products in brain microdialysates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27837829/),%,15,58596,DB00334,Olanzapine
,11499485,signal:noise,"The limit of detection of the assay (signal:noise=3:1) and the lower limit of quantitation were 0.75 ng and 1 ng/ml of olanzapine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),,3:1,63311,DB00334,Olanzapine
,11499485,signal:noise,"The limit of detection of the assay (signal:noise=3:1) and the lower limit of quantitation were 0.75 ng and 1 ng/ml of olanzapine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),ng,0.75,63312,DB00334,Olanzapine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,83,63313,DB00334,Olanzapine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,92,63314,DB00334,Olanzapine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,79,63315,DB00334,Olanzapine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,89,63316,DB00334,Olanzapine
,11499485,Accuracy,"Accuracy was 96% and 93% at 50 and 1 ng/ml, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,96,63317,DB00334,Olanzapine
,11499485,Accuracy,"Accuracy was 96% and 93% at 50 and 1 ng/ml, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,93,63318,DB00334,Olanzapine
,17822717,serum terminal half-life,"Single-dose pharmacokinetic analysis revealed a serum terminal half-life of 1.2-1.5 h for each drug, with no sex differences.",Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17822717/),h,1.2-1.5,64590,DB00334,Olanzapine
,19440083,sample collection time,Mean sample collection time was approximately 15 hours after dose for all groups.,"Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),h,15,67555,DB00334,Olanzapine
,19440083,concentrations,"Mean olanzapine concentrations were 19.7 +/- 11.4, 37.9 +/- 22.8, and 74.5 +/- 43.7 ng/mL for 10-, 20-, and 40-mg doses, respectively.","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],19.7,67556,DB00334,Olanzapine
,19440083,concentrations,"Mean olanzapine concentrations were 19.7 +/- 11.4, 37.9 +/- 22.8, and 74.5 +/- 43.7 ng/mL for 10-, 20-, and 40-mg doses, respectively.","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],37.9,67557,DB00334,Olanzapine
,19440083,concentrations,"Mean olanzapine concentrations were 19.7 +/- 11.4, 37.9 +/- 22.8, and 74.5 +/- 43.7 ng/mL for 10-, 20-, and 40-mg doses, respectively.","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],74.5,67558,DB00334,Olanzapine
,19440083,concentrations,"Olanzapine concentrations were lower in self-reported smokers (16.5 +/- 9.6, 34.2 +/- 20.8, and 60.9 +/- 34.6 ng/mL) than in self-reported nonsmokers (25.6 +/- 12.3, 43.4 +/- 24.7, and 113.2 +/- 44.0 ng/mL) for 10-, 20-, and 40-mg doses, respectively (P </= 0.022).","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],16.5,67559,DB00334,Olanzapine
,19440083,concentrations,"Olanzapine concentrations were lower in self-reported smokers (16.5 +/- 9.6, 34.2 +/- 20.8, and 60.9 +/- 34.6 ng/mL) than in self-reported nonsmokers (25.6 +/- 12.3, 43.4 +/- 24.7, and 113.2 +/- 44.0 ng/mL) for 10-, 20-, and 40-mg doses, respectively (P </= 0.022).","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],34.2,67560,DB00334,Olanzapine
,19440083,concentrations,"Olanzapine concentrations were lower in self-reported smokers (16.5 +/- 9.6, 34.2 +/- 20.8, and 60.9 +/- 34.6 ng/mL) than in self-reported nonsmokers (25.6 +/- 12.3, 43.4 +/- 24.7, and 113.2 +/- 44.0 ng/mL) for 10-, 20-, and 40-mg doses, respectively (P </= 0.022).","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],60.9,67561,DB00334,Olanzapine
,19440083,concentrations,"Olanzapine concentrations were lower in self-reported smokers (16.5 +/- 9.6, 34.2 +/- 20.8, and 60.9 +/- 34.6 ng/mL) than in self-reported nonsmokers (25.6 +/- 12.3, 43.4 +/- 24.7, and 113.2 +/- 44.0 ng/mL) for 10-, 20-, and 40-mg doses, respectively (P </= 0.022).","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],25.6,67562,DB00334,Olanzapine
,19440083,concentrations,"Olanzapine concentrations were lower in self-reported smokers (16.5 +/- 9.6, 34.2 +/- 20.8, and 60.9 +/- 34.6 ng/mL) than in self-reported nonsmokers (25.6 +/- 12.3, 43.4 +/- 24.7, and 113.2 +/- 44.0 ng/mL) for 10-, 20-, and 40-mg doses, respectively (P </= 0.022).","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],43.4,67563,DB00334,Olanzapine
,19440083,concentrations,"Olanzapine concentrations were lower in self-reported smokers (16.5 +/- 9.6, 34.2 +/- 20.8, and 60.9 +/- 34.6 ng/mL) than in self-reported nonsmokers (25.6 +/- 12.3, 43.4 +/- 24.7, and 113.2 +/- 44.0 ng/mL) for 10-, 20-, and 40-mg doses, respectively (P </= 0.022).","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19440083/),[ng] / [ml],113.2,67564,DB00334,Olanzapine
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,71.7,88871,DB00334,Olanzapine
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,64.3,88872,DB00334,Olanzapine
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,75.4,88873,DB00334,Olanzapine
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,72.1,88874,DB00334,Olanzapine
,15018785,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (2.0 mm x 125 mm, 3 microm, Germany) column, using water (formic acid: 2.70 mmol/l, ammonium acetate: 10 mmol/l)-acetonitrile (53:47) as mobile phase, with a flow-rate of 0.16 ml/min.","Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),[ml] / [min],0.16,91882,DB00334,Olanzapine
above,15018785,extraction recoveries,The average extraction recoveries for all the four analysts were at least above 80%.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,80,91883,DB00334,Olanzapine
higher,15018785,recoveries,The methodology recoveries were higher than 91% for the analysts.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,91,91884,DB00334,Olanzapine
,23112405,C(max),Average C(max) following administration of the single 10 mg disintegrating tablet formulation and 10 mg/5 ml suspension were 14.47±4.25 ng/ml and 13.56±3.99 ng/ml respectively.,Evaluation of bioequivalence of two oral formulations of olanzapine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112405/),[ng] / [ml],14.47,96940,DB00334,Olanzapine
,23112405,C(max),Average C(max) following administration of the single 10 mg disintegrating tablet formulation and 10 mg/5 ml suspension were 14.47±4.25 ng/ml and 13.56±3.99 ng/ml respectively.,Evaluation of bioequivalence of two oral formulations of olanzapine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112405/),[ng] / [ml],13.56,96941,DB00334,Olanzapine
,23112405,T(max),"Corresponding median T(max) were 5.0 h and 6.0 h, respectively.",Evaluation of bioequivalence of two oral formulations of olanzapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112405/),h,5.0,96942,DB00334,Olanzapine
,23112405,T(max),"Corresponding median T(max) were 5.0 h and 6.0 h, respectively.",Evaluation of bioequivalence of two oral formulations of olanzapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112405/),h,6.0,96943,DB00334,Olanzapine
,21839766,half-life,Minipump results indicated a monophasic exponential decay and a half-life of 14.8 days (95% CI=13.1-17.1 days).,Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21839766/),d,14.8,103677,DB00334,Olanzapine
,30121590,absorption rate (Ka),The absorption rate (Ka) of olanzapine ranged from 2.85 h-1 to 5.39 h-1 for the different formulations.,Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121590/),1/[h],2.85,112690,DB00334,Olanzapine
,30121590,absorption rate (Ka),The absorption rate (Ka) of olanzapine ranged from 2.85 h-1 to 5.39 h-1 for the different formulations.,Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121590/),1/[h],5.39,112691,DB00334,Olanzapine
,30121590,typical,The typical absorption time delay was 0.877 hour.,Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121590/),h,0.877,112692,DB00334,Olanzapine
,30121590,absorption time delay,The typical absorption time delay was 0.877 hour.,Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121590/),h,0.877,112693,DB00334,Olanzapine
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00334,Olanzapine
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00334,Olanzapine
,16860171,"Cmax,ss","Geometric mean (percent coefficient of variation) values for groups A, B, and C at day 20 were as follows: Cmax,ss 57.8 (40.2), 75.6 (86.7), and 94.1 (50.2) ng/mL, respectively; and AUC: 997 (38.5), 1220 (88.0), and 1630 (53.9) ng . h/mL, respectively.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),[ng] / [ml],57.8,132651,DB00334,Olanzapine
,16860171,"Cmax,ss","Geometric mean (percent coefficient of variation) values for groups A, B, and C at day 20 were as follows: Cmax,ss 57.8 (40.2), 75.6 (86.7), and 94.1 (50.2) ng/mL, respectively; and AUC: 997 (38.5), 1220 (88.0), and 1630 (53.9) ng . h/mL, respectively.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),[ng] / [ml],75.6,132652,DB00334,Olanzapine
,16860171,"Cmax,ss","Geometric mean (percent coefficient of variation) values for groups A, B, and C at day 20 were as follows: Cmax,ss 57.8 (40.2), 75.6 (86.7), and 94.1 (50.2) ng/mL, respectively; and AUC: 997 (38.5), 1220 (88.0), and 1630 (53.9) ng . h/mL, respectively.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),[ng] / [ml],94.1,132653,DB00334,Olanzapine
,16860171,AUC,"Geometric mean (percent coefficient of variation) values for groups A, B, and C at day 20 were as follows: Cmax,ss 57.8 (40.2), 75.6 (86.7), and 94.1 (50.2) ng/mL, respectively; and AUC: 997 (38.5), 1220 (88.0), and 1630 (53.9) ng . h/mL, respectively.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),[h·ng] / [ml],997,132654,DB00334,Olanzapine
,16860171,AUC,"Geometric mean (percent coefficient of variation) values for groups A, B, and C at day 20 were as follows: Cmax,ss 57.8 (40.2), 75.6 (86.7), and 94.1 (50.2) ng/mL, respectively; and AUC: 997 (38.5), 1220 (88.0), and 1630 (53.9) ng . h/mL, respectively.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),[h·ng] / [ml],1220,132655,DB00334,Olanzapine
,16860171,AUC,"Geometric mean (percent coefficient of variation) values for groups A, B, and C at day 20 were as follows: Cmax,ss 57.8 (40.2), 75.6 (86.7), and 94.1 (50.2) ng/mL, respectively; and AUC: 997 (38.5), 1220 (88.0), and 1630 (53.9) ng . h/mL, respectively.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),[h·ng] / [ml],1630,132656,DB00334,Olanzapine
,16860171,weight gain,"Mean (SD) weight gain from baseline to end point was 3.5 (2.81) kg for group A, 3.0 (3.15) kg for group B, and 3.1 (2.22) kg for group C.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),,3.5,132657,DB00334,Olanzapine
,16860171,weight gain,"Mean (SD) weight gain from baseline to end point was 3.5 (2.81) kg for group A, 3.0 (3.15) kg for group B, and 3.1 (2.22) kg for group C.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),kg,3.0,132658,DB00334,Olanzapine
,16860171,weight gain,"Mean (SD) weight gain from baseline to end point was 3.5 (2.81) kg for group A, 3.0 (3.15) kg for group B, and 3.1 (2.22) kg for group C.","A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860171/),,3.1,132659,DB00334,Olanzapine
,23605469,Cmax,"The mean (SD) Cmax, AUC0-t and AUC0-∞ for the test formulation were 15.82 (3.15) ng/mL, 447.19 (100.64) ng.h/L and 570.75 (130.55) ng.h/L respectively.",Single dose bioequivalence study of two brands of olanzapine 10 mg tablets in Iranian healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605469/),[ng] / [ml],15.82,137195,DB00334,Olanzapine
,23605469,AUC0-t,"The mean (SD) Cmax, AUC0-t and AUC0-∞ for the test formulation were 15.82 (3.15) ng/mL, 447.19 (100.64) ng.h/L and 570.75 (130.55) ng.h/L respectively.",Single dose bioequivalence study of two brands of olanzapine 10 mg tablets in Iranian healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605469/),[h·ng] / [l],447.19,137196,DB00334,Olanzapine
,23605469,AUC0-∞,"The mean (SD) Cmax, AUC0-t and AUC0-∞ for the test formulation were 15.82 (3.15) ng/mL, 447.19 (100.64) ng.h/L and 570.75 (130.55) ng.h/L respectively.",Single dose bioequivalence study of two brands of olanzapine 10 mg tablets in Iranian healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23605469/),[h·ng] / [l],570.75,137197,DB00334,Olanzapine
,16982447,C(max),"The main pharmacokinetics parameters of olanzapine were as follow: C(max) was 113.7-/+33.1 microg/L, T(max) 5.07-/+0.65 h, t(1/2) 35.44-/+4.21 h, AUC(0-144) 2,235-/+257 microg.h.L(-1), and AUC(0-inf) 2,516-/+301 microg.h.L(-1).",[Reversed phase high-performance liquid chromatography for determination of plasma olanzapine and pharmacokinetics of olanzapine in healthy Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982447/),[μg] / [l],113.7,139774,DB00334,Olanzapine
,16982447,T(max),"The main pharmacokinetics parameters of olanzapine were as follow: C(max) was 113.7-/+33.1 microg/L, T(max) 5.07-/+0.65 h, t(1/2) 35.44-/+4.21 h, AUC(0-144) 2,235-/+257 microg.h.L(-1), and AUC(0-inf) 2,516-/+301 microg.h.L(-1).",[Reversed phase high-performance liquid chromatography for determination of plasma olanzapine and pharmacokinetics of olanzapine in healthy Chinese volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982447/),h,5.07,139775,DB00334,Olanzapine
,16982447,t(1/2),"The main pharmacokinetics parameters of olanzapine were as follow: C(max) was 113.7-/+33.1 microg/L, T(max) 5.07-/+0.65 h, t(1/2) 35.44-/+4.21 h, AUC(0-144) 2,235-/+257 microg.h.L(-1), and AUC(0-inf) 2,516-/+301 microg.h.L(-1).",[Reversed phase high-performance liquid chromatography for determination of plasma olanzapine and pharmacokinetics of olanzapine in healthy Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982447/),h,35.44,139776,DB00334,Olanzapine
,16982447,AUC(0-144),"The main pharmacokinetics parameters of olanzapine were as follow: C(max) was 113.7-/+33.1 microg/L, T(max) 5.07-/+0.65 h, t(1/2) 35.44-/+4.21 h, AUC(0-144) 2,235-/+257 microg.h.L(-1), and AUC(0-inf) 2,516-/+301 microg.h.L(-1).",[Reversed phase high-performance liquid chromatography for determination of plasma olanzapine and pharmacokinetics of olanzapine in healthy Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982447/),[h·μg] / [l],"2,235",139777,DB00334,Olanzapine
,16982447,AUC(0-inf),"The main pharmacokinetics parameters of olanzapine were as follow: C(max) was 113.7-/+33.1 microg/L, T(max) 5.07-/+0.65 h, t(1/2) 35.44-/+4.21 h, AUC(0-144) 2,235-/+257 microg.h.L(-1), and AUC(0-inf) 2,516-/+301 microg.h.L(-1).",[Reversed phase high-performance liquid chromatography for determination of plasma olanzapine and pharmacokinetics of olanzapine in healthy Chinese volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982447/),[h·μg] / [l],"2,516",139778,DB00334,Olanzapine
,12172335,area under the plasma concentration-time curve,Ritonavir reduced the area under the plasma concentration-time curve of olanzapine from 501 ng.,Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),ng,501,143366,DB00334,Olanzapine
,12172335,half-life,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),h,32,143367,DB00334,Olanzapine
,12172335,half-life,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),h,16,143368,DB00334,Olanzapine
,12172335,peak concentration,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[ng] / [ml],15,143369,DB00334,Olanzapine
,12172335,peak concentration,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[ng] / [ml],9,143370,DB00334,Olanzapine
,12172335,oral clearance,Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir.,Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[l] / [h],20,143371,DB00334,Olanzapine
,12172335,oral clearance,Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir.,Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[l] / [h],43,143372,DB00334,Olanzapine
,27002542,bioavailability,"Though OLZ is an effective agent in the treatment of Schizophrenia, but it exhibits poor bioavailability (57%) due to extensive first-pass metabolism resulted in high dose is required to achieve therapeutic concentration in brain.",Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002542/),%,57,148906,DB00334,Olanzapine
,27002542,particle size,"Results have shown that average particle size and zeta potential of SLNs of GMS and TP were ranged from 165.1 ± 2.2 to 110.5 ± 0.5 and 35.29 ± 1.2 and 66.50 ± 0.7 mV, respectively.",Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002542/),,165.1,148907,DB00334,Olanzapine
,27002542,particle size,"Results have shown that average particle size and zeta potential of SLNs of GMS and TP were ranged from 165.1 ± 2.2 to 110.5 ± 0.5 and 35.29 ± 1.2 and 66.50 ± 0.7 mV, respectively.",Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002542/),mv,110.5,148908,DB00334,Olanzapine
,27002542,particle size,"Results have shown that average particle size and zeta potential of SLNs of GMS and TP were ranged from 165.1 ± 2.2 to 110.5 ± 0.5 and 35.29 ± 1.2 and 66.50 ± 0.7 mV, respectively.",Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002542/),mv,35.29,148909,DB00334,Olanzapine
,27002542,zeta potential,"Results have shown that average particle size and zeta potential of SLNs of GMS and TP were ranged from 165.1 ± 2.2 to 110.5 ± 0.5 and 35.29 ± 1.2 and 66.50 ± 0.7 mV, respectively.",Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002542/),mv,110.5,148910,DB00334,Olanzapine
,27002542,zeta potential,"Results have shown that average particle size and zeta potential of SLNs of GMS and TP were ranged from 165.1 ± 2.2 to 110.5 ± 0.5 and 35.29 ± 1.2 and 66.50 ± 0.7 mV, respectively.",Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002542/),mv,66.50,148911,DB00334,Olanzapine
,20939188,flow rate,An isocratic program was used at a flow rate of 0.4 m x min(-1) with mobile phase consisting of acetonitrile and ammonium buffer (pH 8).,Development and validation of a liquid chromatography-isotope dilution tandem mass spectrometry for determination of olanzapine in human plasma and its application to bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20939188/),[m] / [min],0.4,153233,DB00334,Olanzapine
,26129833,flow rate,The analytes were chromatographed on a Waters Acquity H class UPLC system using isocratic mobile phase conditions at a flow rate of 0.3 mL/min and Acquity UPLC BEH shield RP18 column maintained at 40°C.,"Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),[ml] / [min],0.3,153465,DB00334,Olanzapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,0.9,153466,DB00334,Olanzapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.4,153467,DB00334,Olanzapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,.,153468,DB00334,Olanzapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.8,153469,DB00334,Olanzapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,3.1,153470,DB00334,Olanzapine
,26129833,total run time,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,4,153471,DB00334,Olanzapine
,21839863,entrapment efficiency,The NP were 91.2±5.2 nm in diameter and had entrapment efficiency 68.91±2.31%.,Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21839863/),%,68.91,154959,DB00334,Olanzapine
,20297865,oral clearance (CL/F),The typical model estimates were 13.6 L/h (70 kg female patient) for oral clearance (CL/F) and 899 L for oral volume of distribution (V/F).,Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297865/),[l] / [h],13.6,154960,DB00334,Olanzapine
,20297865,oral volume of distribution (V/F),The typical model estimates were 13.6 L/h (70 kg female patient) for oral clearance (CL/F) and 899 L for oral volume of distribution (V/F).,Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297865/),l,899,154961,DB00334,Olanzapine
,16504450,absolute recovery,The average absolute recovery of olanzapine from spiked plasma samples was 85.5+/-1.9%.,Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504450/),%,85.5,157836,DB00334,Olanzapine
,16504450,run time,A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504450/),min,2.0,157837,DB00334,Olanzapine
,21913873,Frel,In vivo studies of optimized olanzapine patch in rabbit model revealed prolongation of action with Frel 116.09% during 72-h study period.,"Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913873/),,116,159499,DB00334,Olanzapine
,16778724,flow-rate,The chromatographic separation required 6 minutes at a flow-rate of 1.0 mL/min and was carried out on a Water Spherisorb S5 C6 analytical column (250 mm x 4.6 mm ID) with a mobile phase water-acetonitrile 55:45 vol/vol containing 0.009 moL/L eptansulfonic acid sodium salt and 0.06 mol/L potassium phosphate monobasic pH 2.7.,Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),[ml] / [min],1.0,166730,DB00334,Olanzapine
,16778724,recoveries,"Mean recoveries for olanzapine and internal standard were 89.4+/-3.3% and 90.4+/-1.0%, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),%,89.4,166731,DB00334,Olanzapine
,16778724,recoveries,"Mean recoveries for olanzapine and internal standard were 89.4+/-3.3% and 90.4+/-1.0%, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),%,90.4,166732,DB00334,Olanzapine
,16778724,Limit of detection,"Limit of detection and limit of quantification for olanzapine were 2 and 5 ng/mL, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),[ng] / [ml],2,166733,DB00334,Olanzapine
,16778724,limit of quantification,"Limit of detection and limit of quantification for olanzapine were 2 and 5 ng/mL, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),[ng] / [ml],5,166734,DB00334,Olanzapine
,32497307,CL/F,"Typical CL/F and apparent volume of distribution (scaled to 70 kg) were 16.8 L/h (21% RSE) and 663 L (13% RSE), respectively.",Population pharmacokinetics of olanzapine in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32497307/),[l] / [h],16.8,167055,DB00334,Olanzapine
,32497307,apparent volume of distribution,"Typical CL/F and apparent volume of distribution (scaled to 70 kg) were 16.8 L/h (21% RSE) and 663 L (13% RSE), respectively.",Population pharmacokinetics of olanzapine in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32497307/),l,663,167056,DB00334,Olanzapine
>,33230696,C/D ratio,"The Olanzapine concentration to dose (C/D) ratio was positively correlated with the percentage of improvement in the total PANSS (r = 0.46, p = 0.004), and a C/D ratio > 2.12 was identified as a positive predictor of a good response (percentage of improvement > 30%) after 2 months of treatment.",The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33230696/),,2.12,167263,DB00334,Olanzapine
,12352274,concentrations,Fluvoxamine concentrations were 48 +/- 26 ng/mL on week 1 and 83 +/- 47 ng/mL on week 8.,Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352274/),ng,48,177424,DB00334,Olanzapine
,24815672,Half-life,"Half-life was ∼30 days, controlled by the slow rate of intramuscular absorption rather than the 30-h elimination rate-based half-life of oral olanzapine.",Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815672/),d,∼30,181340,DB00334,Olanzapine
,24815672,Half-life,"Half-life was ∼30 days, controlled by the slow rate of intramuscular absorption rather than the 30-h elimination rate-based half-life of oral olanzapine.",Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815672/),h,30,181341,DB00334,Olanzapine
,24815672,steady-state concentrations,"Concentrations were similar to oral olanzapine and proportional to the dose; the average steady-state concentrations (10th-90th percentile) for the 150, 210, and 300 mg/2-week doses were 16-32, 15-55, and 20-67 ng/ml, respectively, and those for the 300 and 405 mg/4-week doses were 19-48 and 19-62 ng/ml, respectively.",Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815672/),[ng] / [ml],16-32,181342,DB00334,Olanzapine
,24815672,steady-state concentrations,"Concentrations were similar to oral olanzapine and proportional to the dose; the average steady-state concentrations (10th-90th percentile) for the 150, 210, and 300 mg/2-week doses were 16-32, 15-55, and 20-67 ng/ml, respectively, and those for the 300 and 405 mg/4-week doses were 19-48 and 19-62 ng/ml, respectively.",Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815672/),[ng] / [ml],15-55,181343,DB00334,Olanzapine
,24815672,steady-state concentrations,"Concentrations were similar to oral olanzapine and proportional to the dose; the average steady-state concentrations (10th-90th percentile) for the 150, 210, and 300 mg/2-week doses were 16-32, 15-55, and 20-67 ng/ml, respectively, and those for the 300 and 405 mg/4-week doses were 19-48 and 19-62 ng/ml, respectively.",Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815672/),[ng] / [ml],20-67,181344,DB00334,Olanzapine
,24815672,steady-state concentrations,"Concentrations were similar to oral olanzapine and proportional to the dose; the average steady-state concentrations (10th-90th percentile) for the 150, 210, and 300 mg/2-week doses were 16-32, 15-55, and 20-67 ng/ml, respectively, and those for the 300 and 405 mg/4-week doses were 19-48 and 19-62 ng/ml, respectively.",Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815672/),[ng] / [ml],19-48,181345,DB00334,Olanzapine
,24815672,steady-state concentrations,"Concentrations were similar to oral olanzapine and proportional to the dose; the average steady-state concentrations (10th-90th percentile) for the 150, 210, and 300 mg/2-week doses were 16-32, 15-55, and 20-67 ng/ml, respectively, and those for the 300 and 405 mg/4-week doses were 19-48 and 19-62 ng/ml, respectively.",Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815672/),[ng] / [ml],19-62,181346,DB00334,Olanzapine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],15.3,189466,DB00334,Olanzapine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],4.9,189467,DB00334,Olanzapine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],2.5,189468,DB00334,Olanzapine
,23684658,brain/blood ratio,"The significantly (P<0.05) higher values for F11 micelles (i.n.); brain/blood ratio (0.92), drug targeting index (5.20), drug targeting efficiency (520.26%) and direct transport percentage (80.76%) confirm the development of a promising non-invasive OZ-loaded nose-to-brain delivery system.","Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23684658/),,0.92,198621,DB00334,Olanzapine
,23684658,drug targeting index,"The significantly (P<0.05) higher values for F11 micelles (i.n.); brain/blood ratio (0.92), drug targeting index (5.20), drug targeting efficiency (520.26%) and direct transport percentage (80.76%) confirm the development of a promising non-invasive OZ-loaded nose-to-brain delivery system.","Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23684658/),,5.20,198622,DB00334,Olanzapine
,18308793,D,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202598,DB00334,Olanzapine
,18308793,RO,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202599,DB00334,Olanzapine
,18308793,C(P),"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),[ng] / [ml],9.4-60.5,202600,DB00334,Olanzapine
,11073289,oral clearance,"The mean (+/- SD) oral clearance and elimination half-life of olanzapine were 51.5+/-61.6 l/h and 30.9+/-4.3 hours, respectively.",Disposition of olanzapine in Chinese schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073289/),[l] / [h],51.5,207781,DB00334,Olanzapine
,11073289,elimination half-life,"The mean (+/- SD) oral clearance and elimination half-life of olanzapine were 51.5+/-61.6 l/h and 30.9+/-4.3 hours, respectively.",Disposition of olanzapine in Chinese schizophrenic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073289/),h,30.9,207782,DB00334,Olanzapine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,75.6,210192,DB00334,Olanzapine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,66.8,210193,DB00334,Olanzapine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,72.3,210194,DB00334,Olanzapine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,62.0,210195,DB00334,Olanzapine
,30008307,extraction recoveries,"The extraction recoveries were 75%-85% for olanzapine and olanzapine‑d3, and 58%-69% for fluoxetine, norfluoxetine, and their deuterated internal standards.","Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30008307/),%,75,211305,DB00334,Olanzapine
,30008307,extraction recoveries,"The extraction recoveries were 75%-85% for olanzapine and olanzapine‑d3, and 58%-69% for fluoxetine, norfluoxetine, and their deuterated internal standards.","Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30008307/),%,58,211306,DB00334,Olanzapine
,17443131,occupancy,"Mean striatal D(2) receptor occupancy, as measured by [(11)C]-raclopride PET, was 69% on oral olanzapine (5-20 mg/day) and 50% (trough) on OP depot at steady state.",D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443131/),%,69,214022,DB00334,Olanzapine
,17443131,occupancy,"Mean striatal D(2) receptor occupancy, as measured by [(11)C]-raclopride PET, was 69% on oral olanzapine (5-20 mg/day) and 50% (trough) on OP depot at steady state.",D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443131/),%,50,214023,DB00334,Olanzapine
,17443131,occupancy,"OP depot resulted in mean D(2) receptor occupancy of approximately 60% or higher at the end of the 6-month study period, a level consistent with antipsychotic efficacy and found during treatment with oral olanzapine.",D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443131/),%,60,214024,DB00334,Olanzapine
,25744410,peak concentration,A pharmacokinetic analysis demonstrated that the maximum concentration of olanzapine in plasma (Cmax) occurred at 6h with a peak concentration of 276.5ng/ml after a single oral treatment and with a plasma elimination half-life of 3.5h after peak.,Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744410/),[ng] / [ml],276.5,214378,DB00334,Olanzapine
,25744410,plasma elimination half-life,A pharmacokinetic analysis demonstrated that the maximum concentration of olanzapine in plasma (Cmax) occurred at 6h with a peak concentration of 276.5ng/ml after a single oral treatment and with a plasma elimination half-life of 3.5h after peak.,Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744410/),h,3.5,214379,DB00334,Olanzapine
,18199892,clearance,"The population mean olanzapine clearance and volume of distribution were 16.1 L/h and 2150 L, respectively.","Sex, race, and smoking impact olanzapine exposure. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199892/),[l] / [h],16.1,218899,DB00334,Olanzapine
,18199892,volume of distribution,"The population mean olanzapine clearance and volume of distribution were 16.1 L/h and 2150 L, respectively.","Sex, race, and smoking impact olanzapine exposure. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199892/),l,2150,218900,DB00334,Olanzapine
,18199892,Elimination,"Elimination of olanzapine varied nearly 10-fold (range, 6.66-67.96 L/h).","Sex, race, and smoking impact olanzapine exposure. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199892/),[l] / [h],6.66-67.96,218901,DB00334,Olanzapine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,73,219858,DB00334,Olanzapine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,55,219859,DB00334,Olanzapine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,32,219860,DB00334,Olanzapine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,3,219861,DB00334,Olanzapine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,9,219862,DB00334,Olanzapine
,10770461,apparent mean oral clearance,Olanzapine pharmacokinetic evaluation gave an apparent mean oral clearance of 9.6 +/- 2.4 L/hr and a mean elimination half-life of 37.2 +/- 5.1 hours in these young patients.,Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770461/),[l] / [h],9.6,221695,DB00334,Olanzapine
,10770461,elimination half-life,Olanzapine pharmacokinetic evaluation gave an apparent mean oral clearance of 9.6 +/- 2.4 L/hr and a mean elimination half-life of 37.2 +/- 5.1 hours in these young patients.,Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770461/),h,37.2,221696,DB00334,Olanzapine
,25491375,flow rate,The flow rate was 1.2 mL/min.,The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),[ml] / [min],1.2,224818,DB00334,Olanzapine
,25491375,retention times,"The retention times for OLZ and the IS were 0.78 and 1.04 min, respectively.",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),min,0.78,224819,DB00334,Olanzapine
,25491375,retention times,"The retention times for OLZ and the IS were 0.78 and 1.04 min, respectively.",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),min,1.04,224820,DB00334,Olanzapine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,313.1,224821,DB00334,Olanzapine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,256.1,224822,DB00334,Olanzapine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,278.1,224823,DB00334,Olanzapine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,260.2,224824,DB00334,Olanzapine
,25491375,recovery,"3. No significant matrix effects were observed on OLZ and the IS retention times, and the mean recovery of OLZ was 90.08%.",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),%,90.08,224825,DB00334,Olanzapine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,76,224901,DB00334,Olanzapine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,56,224902,DB00334,Olanzapine
,33493118,MRT,"The optimized system showed significantly (P < 0.05) prolonged MRT (8.47 h), higher Cmax (22.12± 0.40 ng/ml) and Tmax (2.0 h) values compared to drug suspension.","Olanzapine Mesoporous Nanostructured Lipid Carrier: Optimization, Characterization, In Vivo Assessment, and Physiologically Based Pharmacokinetic Modeling. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493118/),h,8.47,227846,DB00334,Olanzapine
,33493118,Cmax,"The optimized system showed significantly (P < 0.05) prolonged MRT (8.47 h), higher Cmax (22.12± 0.40 ng/ml) and Tmax (2.0 h) values compared to drug suspension.","Olanzapine Mesoporous Nanostructured Lipid Carrier: Optimization, Characterization, In Vivo Assessment, and Physiologically Based Pharmacokinetic Modeling. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493118/),[ng] / [ml],22.12,227847,DB00334,Olanzapine
,33493118,Tmax,"The optimized system showed significantly (P < 0.05) prolonged MRT (8.47 h), higher Cmax (22.12± 0.40 ng/ml) and Tmax (2.0 h) values compared to drug suspension.","Olanzapine Mesoporous Nanostructured Lipid Carrier: Optimization, Characterization, In Vivo Assessment, and Physiologically Based Pharmacokinetic Modeling. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493118/),h,2.0,227848,DB00334,Olanzapine
,22933048,Cmax,"The mean (SD) Cmax, AUC0-144, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 18.91 (5.320) vs. 18.44 (4.758) ng/mL, 582.9 (118.23) vs. 587.3 (127.12) ng/mL · h, and 615.4 (131.39) vs. 615.8 (137.45) ng/mL · h.","Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22933048/),[ng] / [ml],18.91,229952,DB00334,Olanzapine
,22933048,AUC0-144,"The mean (SD) Cmax, AUC0-144, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 18.91 (5.320) vs. 18.44 (4.758) ng/mL, 582.9 (118.23) vs. 587.3 (127.12) ng/mL · h, and 615.4 (131.39) vs. 615.8 (137.45) ng/mL · h.","Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22933048/),[ng] / [ml],18.44,229953,DB00334,Olanzapine
,22933048,AUC0-144,"The mean (SD) Cmax, AUC0-144, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 18.91 (5.320) vs. 18.44 (4.758) ng/mL, 582.9 (118.23) vs. 587.3 (127.12) ng/mL · h, and 615.4 (131.39) vs. 615.8 (137.45) ng/mL · h.","Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22933048/),[ng] / [h·ml],582.9,229954,DB00334,Olanzapine
,22933048,AUC0-∞,"The mean (SD) Cmax, AUC0-144, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 18.91 (5.320) vs. 18.44 (4.758) ng/mL, 582.9 (118.23) vs. 587.3 (127.12) ng/mL · h, and 615.4 (131.39) vs. 615.8 (137.45) ng/mL · h.","Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22933048/),[ng] / [h·ml],587.3,229955,DB00334,Olanzapine
,22933048,AUC0-∞,"The mean (SD) Cmax, AUC0-144, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 18.91 (5.320) vs. 18.44 (4.758) ng/mL, 582.9 (118.23) vs. 587.3 (127.12) ng/mL · h, and 615.4 (131.39) vs. 615.8 (137.45) ng/mL · h.","Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22933048/),[ng] / [h·ml],615.4,229956,DB00334,Olanzapine
,22933048,AUC0-∞,"The mean (SD) Cmax, AUC0-144, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 18.91 (5.320) vs. 18.44 (4.758) ng/mL, 582.9 (118.23) vs. 587.3 (127.12) ng/mL · h, and 615.4 (131.39) vs. 615.8 (137.45) ng/mL · h.","Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22933048/),[ng] / [h·ml],615.8,229957,DB00334,Olanzapine
,22933048,relative bioavailability,The relative bioavailability of the test formulation to reference formulation was 100.1%.,"Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22933048/),%,100.1,229958,DB00334,Olanzapine
,32609960,time to maximum concentration,"Median time to maximum concentration was less for INP105 (15, 10, and 9.5 min for 5 mg, 10 mg, and 15 mg, respectively) than for OLZ IM (20 and 15 min for 5 mg and 10 mg, respectively) or OLZ ODT (120 min).","The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32609960/),min,15,231408,DB00334,Olanzapine
,32609960,time to maximum concentration,"Median time to maximum concentration was less for INP105 (15, 10, and 9.5 min for 5 mg, 10 mg, and 15 mg, respectively) than for OLZ IM (20 and 15 min for 5 mg and 10 mg, respectively) or OLZ ODT (120 min).","The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32609960/),min,10,231409,DB00334,Olanzapine
,32609960,time to maximum concentration,"Median time to maximum concentration was less for INP105 (15, 10, and 9.5 min for 5 mg, 10 mg, and 15 mg, respectively) than for OLZ IM (20 and 15 min for 5 mg and 10 mg, respectively) or OLZ ODT (120 min).","The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32609960/),min,9.5,231410,DB00334,Olanzapine
,32609960,time to maximum concentration,"Median time to maximum concentration was less for INP105 (15, 10, and 9.5 min for 5 mg, 10 mg, and 15 mg, respectively) than for OLZ IM (20 and 15 min for 5 mg and 10 mg, respectively) or OLZ ODT (120 min).","The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32609960/),min,20,231411,DB00334,Olanzapine
,32609960,time to maximum concentration,"Median time to maximum concentration was less for INP105 (15, 10, and 9.5 min for 5 mg, 10 mg, and 15 mg, respectively) than for OLZ IM (20 and 15 min for 5 mg and 10 mg, respectively) or OLZ ODT (120 min).","The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32609960/),min,120,231412,DB00334,Olanzapine
,27154255,Particle size,Particle size of OLZ in all formulations ranged between 42 and 58μm.,Solid microcrystalline dispersion films as a new strategy to improve the dissolution rate of poorly water soluble drugs: A case study using olanzapine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154255/),μm,42 and 58,233160,DB00334,Olanzapine
,8738191,plasma elimination half-times,"The plasma elimination half-times for olanzapine and the two metabolites were approximately the same, ranging from 3.3 to 4.4 h.",Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738191/),h,3.3 to 4.4,234362,DB00334,Olanzapine
,30549068,recovery,Average recovery of the extraction procedure was 94.8%.,Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30549068/),%,94.8,238267,DB00334,Olanzapine
,30549068,flow rate,"Chromatographic separation was performed on reversed-phase C18 column (250 × 2.0 mm, 5 μm) using mixture of deionized water (trifluoro acetic acid 0.1%)-acetonitrile (20:80, v/v) as mobile phase at a flow rate of 1 mL/min.",Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30549068/),[ml] / [min],1,238268,DB00334,Olanzapine
,30549068,total run time,Irbesartan was used as internal standart and total run time was 2.5 min.,Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30549068/),min,2.5,238269,DB00334,Olanzapine
,22023211,cumulative amount of drug permeated,Corn oil containing unsaturated fatty acids was found to be promising natural permeation enhancer for transdermal delivery of olanzapine with greatest cumulative amount of drug permeated (1010.68 μg/cm²/h) up to 24 h and caused no skin irritation.,Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22023211/),[μg] / [cm²·h],1010.68,241405,DB00334,Olanzapine
,22023211,relative bioavailability,The calculated relative bioavailability of TDDS was 113.6 % as compared to oral administration of olanzapine.,Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22023211/),%,113.6,241406,DB00334,Olanzapine
,26295148,zeta potential,OLA-LNC were successfully developed with a particle size of 142 ± 4 nm and a zeta potential of -19.6 ± 0.6 mV.,Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26295148/),mv,-19.6,242212,DB00334,Olanzapine
,26295148,relative bioavailability,"Higher olanzapine concentrations and AUC(0-12 h) were found in plasma and tissues evaluated after the administration of OLA-LNC compared to the drug in the free form, resulting in a relative bioavailability of 226.7% in the plasma.",Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26295148/),%,226.7,242213,DB00334,Olanzapine
,9638310,tmax,This study demonstrated that [14C]olanzapine and/or metabolites were rapidly absorbed and widely distributed with a tmax of 2 h postdose in most tissues.,Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638310/),h,2,248868,DB00334,Olanzapine
,9638310,tmax,The placental transfer studies indicated that all tissues analyzed had a tmax of 1 or 3 h postdose with maternal liver consistently containing high concentrations of radiocarbon.,Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638310/),h,1,248869,DB00334,Olanzapine
,9638310,tmax,The placental transfer studies indicated that all tissues analyzed had a tmax of 1 or 3 h postdose with maternal liver consistently containing high concentrations of radiocarbon.,Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638310/),h,3,248870,DB00334,Olanzapine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,24.2,260824,DB00334,Olanzapine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,10.3,260825,DB00334,Olanzapine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,75.2,260826,DB00334,Olanzapine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,66.6,260827,DB00334,Olanzapine
,11699614,CLoral,"Moreover, there were no significant differences in any of the olanzapine pharmacokinetic parameters between the CYP2D6 PMs and EMs (CLoral=0.246 l h(-1) kg(-1) and 0.203 l h(-1) kg(-1), respectively, P=0.30).",Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699614/),[l] / [h·kg],0.246,261045,DB00334,Olanzapine
,11699614,CLoral,"Moreover, there were no significant differences in any of the olanzapine pharmacokinetic parameters between the CYP2D6 PMs and EMs (CLoral=0.246 l h(-1) kg(-1) and 0.203 l h(-1) kg(-1), respectively, P=0.30).",Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699614/),[l] / [h·kg],0.203,261046,DB00334,Olanzapine
greater,11254198,extraction efficiencies,The extraction efficiencies of olanzapine and internal standard (LY170158) were greater than 82% in brain tissue.,Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254198/),%,82,261752,DB00334,Olanzapine
,33677821,absorption rate constant (Ka),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),1/[h],0.30,265598,DB00334,Olanzapine
,33677821,apparent clearance (CL/F),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),[l] / [h],12.88,265599,DB00334,Olanzapine
,33677821,apparent distribution volume (V/F),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),l,754.41,265600,DB00334,Olanzapine
,16637792,time to reach maximum concentration,"For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean +/- SD 1.9 +/- 1.3 vs 4.0 +/- 3.0 hrs, p = 0.025), possibly because of the anticholinergic properties associated with olanzapine.",Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637792/),h,1.9,271319,DB00334,Olanzapine
,16637792,time to reach maximum concentration,"For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean +/- SD 1.9 +/- 1.3 vs 4.0 +/- 3.0 hrs, p = 0.025), possibly because of the anticholinergic properties associated with olanzapine.",Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637792/),h,4.0,271320,DB00334,Olanzapine
,20948432,Relapse rates,"Relapse rates for the therapeutic LAI doses (≥ 150 mg) varied depending on earlier oral dose, ranging from 1.5% (patients switched from 10 mg/day to 300 mg/2 weeks) to 18.8% (patients switched from 20 mg/day to 150 mg/2 weeks).",Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20948432/),%,1.,271321,DB00334,Olanzapine
,20948432,Relapse rates,"Relapse rates for the therapeutic LAI doses (≥ 150 mg) varied depending on earlier oral dose, ranging from 1.5% (patients switched from 10 mg/day to 300 mg/2 weeks) to 18.8% (patients switched from 20 mg/day to 150 mg/2 weeks).",Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20948432/),%,18,271322,DB00334,Olanzapine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],31,272547,DB00334,Olanzapine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],32,272548,DB00334,Olanzapine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],36,272549,DB00334,Olanzapine
